Clinical trials: Waldenstrom Macroglobulinaemia
Follicular Lymphoma, Small Lymphocytic Lymphoma
Imexon for Relapsed Follicular and Aggressive Lymphomas
The purpose of this study is to determine whether Amplimexon (imexon for injection) is effective in the treatment of indolent and aggressive lymphomas that have progressed after treatment with standard therapies.
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma
- Trial name
- ULYM11011 (NCT01314014)
- Testing
- Imexon
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Rochester
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and…
- Trial name
- NCT00142116
- Testing
- Thalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Steven P. Treon, MD, PhD
Chronic Lymphocytic Leukemia, Follicular Lymphoma
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well ixazomib citrate and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that grows slowly (indolent).
- Conditions
- Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02339922
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03277729
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Bridalveil (NCT01732926)
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 144 sites in United States, Australia and 13 more
- Volunteers
- 475 people
- Sponsor
- Gilead Sciences
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Follicular Lymphoma, Small Lymphocytic Lymphoma
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- DELTA (NCT01282424)
- Testing
- Idelalisib
- Where
- 41 sites in United States, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT03674411
- Testing
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Waldenstrom Macroglobulinaemia
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of…
- Trial name
- NCT00811733
- Testing
- Ofatumumab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Primary objective: To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen.
- Trial name
- NCT00536978
- Testing
- ARA-C, BCNU, Campath-1H
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of lenalidomide when given together with temsirolimus and to see how well it works in treating patients with Hodgkin lymphoma or non-Hodgkin lymphoma that has come…
- Conditions
- AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma
- Trial name
- NCT01076543
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Temsirolimus
- Where
- 11 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia
- Trial name
- NCT04191187
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Hematologic Malignancies
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy.
- Trial name
- NCT02988466
- Testing
- Haplo HCT <55 years old, Haplo HCT ≥55 years old, GVHD Prophylaxis
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin…
- Conditions
- Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT02242045
- Testing
- Idelalisib
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Gilead Sciences
Waldenstrom Macroglobulinemia
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
This study is for patients who have previously been treated for Waldenström's macroglobulinaemia (WM) and their disease has either not responded (known as refractory disease) or has returned (known as relapsed disease).
- Trial name
- PembroWM (NCT03630042)
- Testing
- Pembrolizumab, Rituximab
- Where
- 9 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- University College, London
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University